Migraine Clinical Trial
Official title:
the Prevalance of Headache and Effects on Biopsychosocial Status in Undergraduate Students
Verified date | September 2023 |
Source | Hacettepe University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The primary aim of this study was to determine the prevalence of headache in undergraduate students. The frequency, duration, localizations and symptoms of headache will be determined with the information obtained as a result of the forms filled in by the participants. The second aim of this study is to examine the effects of headache on physical, social and psychological status in undergraduate student(participants) from a biopsychosocial perspective.
Status | Completed |
Enrollment | 257 |
Est. completion date | June 12, 2023 |
Est. primary completion date | June 2, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Having undergraduate education at Hacettepe University Faculty of Physical Therapy and Rehabilitation. - be over 18 years old. - To know Turkish. - Volunteer to participate in the study. Exclusion Criteria: - Being over 65 years old. - Having any neurological problem except headache. - Any additional problems that prevent him from completing the questionnaires and scales. to be |
Country | Name | City | State |
---|---|---|---|
Turkey | Hacettepe Univercity | Ankara |
Lead Sponsor | Collaborator |
---|---|
seyda öztürk |
Turkey,
Baxter P. ICF: health vs disease. Dev Med Child Neurol. 2004 May;46(5):291. doi: 10.1017/s0012162204000477. No abstract available. — View Citation
Bellini B, Arruda M, Cescut A, Saulle C, Persico A, Carotenuto M, Gatta M, Nacinovich R, Piazza FP, Termine C, Tozzi E, Lucchese F, Guidetti V. Headache and comorbidity in children and adolescents. J Headache Pain. 2013 Sep 24;14(1):79. doi: 10.1186/1129-2377-14-79. — View Citation
Stovner Lj, Hagen K, Jensen R, Katsarava Z, Lipton R, Scher A, Steiner T, Zwart JA. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007 Mar;27(3):193-210. doi: 10.1111/j.1468-2982.2007.01288.x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | prevelance | Headache prevalence in undergraduate students | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Sleep Quality- Pittsburgh Sleep Quality Index- A minimum of 0 and a maximum of 21 points can be obtained from this scale. The higher the score, the worse the sleep quality. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Anxiety Depression Level- Hospital Anxiety Depression Scale- A minimum of 0 and a maximum of 42 points can be obtained from this scale. The higher the score, the higher the severity of anxiety depression. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Personal Information Form- In this form, participants' height, weight, age, gender, smoking and alcohol use, whether they have a headache or not, and their education level are questioned. there is no minimum or maximum value | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Self Compassion- Self Compassion Scale- A minimum of 24 and a maximum of 130 points can be obtained from this scale. The higher the score, the higher the level of self-compassion. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Fatigue Level- The Fatigue Severity Scale - A minimum of 0 and a maximum of 9 points can be obtained from this scale. The higher the score, the higher the severity of fatigue. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Body Awareness- Body Awareness Scale- A minimum of 18 and a maximum of 126 points can be obtained from this scale. The higher the score, the higher the body awareness. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Physical Activity Level- International Physical Activity Questionnaire - The scale score is defined in 3 different categories as a result of the scores obtained in the range of minimum 0 and maximum +3000 points. As the score obtained from the scale increases, the level of physical activity increases. results are reported in categories. (low activity levels, moderate activity levels, or high activity levels). | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Cervical Range of Motion- The participant is asked to evaluate the cervical joint range of motion in 6 directions (flexion, extension, right/left lateral flexion, and right/left rotation). The minimum score is 0, the maximum score is 10. The higher the score, the higher the range of motion. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Quality of Life-Short Form-12 (SF-12) - The total score ranges from 0-100. The higher the score, the higher the quality of life. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Discomfort intolerance level- Discomfort Intolerance Scale- The total score changes from a minimum of 0 to a maximum of 42 points. As the total scores of the participants increase, it is accepted that the tolerance to the discomfort is higher. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Numeric Rate Scale- A minimum of 0 and a maximum of 10 points is obtained from the scale. A high score indicates a high headache. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | ID- MIGRAINE TEST-There are 3 questions in this test. It is stated that the participants who answer yes to two of the questions are more likely to have migraine. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | Headache Impact Test (HIT-6™)- A minimum of 36 points and a maximum of 78 points are taken from this scale. The higher the total score obtained from the questionnaire, the worse the quality of life of the participants with headaches. | april 2023-may 2023 | |
Secondary | effect of headache on biopsychosocial status | In this form, participants with headaches are asked about the severity of the pain, the frequency, location and duration of the pain, whether there is a family history of headaches, etc. | april 2023-may 2023 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |